Enhertu Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of her2 positive cancers, limitations of conventional chemotherapy, early success of targeted therapies, advances in molecular diagnostics, rising oncology drug approvals.

The growth in the forecast period can be attributed to expanding indications for antibody drug conjugates, growth in her2 testing adoption, increasing demand for precision cancer therapies, strong oncology research funding, favorable clinical trial outcomes. Major trends in the forecast period include antibody drug conjugate cancer therapies, targeted her2 directed treatments, expansion of precision oncology, rising use of biomarker based cancer care, shift toward advanced line targeted therapies.

The increasing prevalence of breast cancer is expected to drive the growth of the enhertu market in the coming years. Breast cancer is a type of cancer that originates in the cells of the breast, often in the milk ducts or lobules, and can spread to other parts of the body. The rising incidence of breast cancer is influenced by factors such as an aging population, genetic predispositions, lifestyle factors including poor diet and physical inactivity, environmental exposures, and improvements in detection and screening methods. Enhertu provides targeted therapy for breast cancer by delivering a potent combination of chemotherapy and HER2-directed treatment, improving outcomes for patients with advanced or metastatic HER2-positive breast cancer. For example, in September 2023, Breast Cancer Now, a UK-based breast cancer charity, reported that approximately 600,000 people in the UK were living after a breast cancer diagnosis, with this number expected to rise to 1.2 million by 2030. Therefore, the increasing prevalence of breast cancer is supporting the growth of the enhertu market.

A key trend in the enhertu market is conducting clinical trials to expand its indications for treating various cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer, beyond its established use in HER2-positive breast cancer. These trials aim to position Enhertu as a targeted therapy with demonstrated improvements in patient outcomes. For instance, in April 2024, Daiichi Sankyo, a Japan-based pharmaceutical company, and AstraZeneca plc, a UK-based pharmaceutical company, announced results from the DESTINY-Breast06 Phase 3 trial of ENHERTU (trastuzumab deruxtecan). The study showed that ENHERTU significantly improves progression-free survival (PFS) in patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer who had received one or more lines of endocrine therapy. This marks the first time a HER2-directed therapy has shown a clinically meaningful benefit for this specific patient population.

In November 2024, Daiichi Sankyo entered a $300 million license agreement with Alteogene, a South Korea-based company specializing in antibody-drug conjugates. Through this collaboration, Daiichi Sankyo aims to leverage Alteogene’s proprietary technologies to develop a subcutaneous version of Enhertu (fam-trastuzumab deruxtecan-nxki), an antibody-drug conjugate partnered with AstraZeneca, offering a more convenient and potentially less invasive treatment option for patients.

Major companies operating in the enhertu market are AstraZeneca Plc, Daiichi Sankyo Co. Ltd.

North America was the largest region in the enhertu market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enhertu market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the enhertu market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the enhertu market by raising costs for specialized drug conjugation components, manufacturing equipment, and international supply chains. Oncology centers and hospital pharmacies in import dependent regions are most affected by these pricing pressures. This can influence treatment affordability and access in some markets. At the same time, tariffs are driving investment in local high value oncology manufacturing. This supports regional innovation and long term supply stability.

The enhertu market research report is one of a series of new reports that provides enhertu market statistics, including enhertu industry global market size, regional shares, competitors with a enhertu market share, detailed enhertu market segments, market trends and opportunities, and any further data you may need to thrive in the enhertu industry. This enhertu market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Enhertu (trastuzumab deruxtecan) is a targeted cancer therapy used to treat adults with HER2-positive breast cancer that is metastatic or inoperable. It combines a monoclonal antibody (trastuzumab) that targets HER2 with a chemotherapy agent (deruxtecan) to inhibit cancer cell growth.

The primary indications for enhertu include HER2-positive metastatic breast cancer, HER2-low metastatic breast cancer, HER2-mutant non-small cell lung cancer (NSCLC), and HER2-positive metastatic gastric cancer. HER2-positive breast cancer is defined by the presence of the human epidermal growth factor receptor 2 (HER2) protein. The therapy is used across multiple treatment lines, including first-line, second-line, and third-line therapy, and is distributed through hospital pharmacies, specialty pharmacies, and retail pharmacies.

The enhertu market consists of sales of lyophilized powder for injection and IV infusions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.